Are These 5 Misconceptions Keeping You From Modernizing QC?

Biopharma companies face the challenge of navigating competing forces as they move toward commercialization. From the early phases of drug development, teams must efficiently scale operations without increasing costs or delaying market entry. However, advancements in novel modalities have led to more complex and expensive manufacturing and testing processes. Additionally, as regulatory oversight of virtual biotech intensifies, companies that outsource these tasks must effectively scale their external partners and ensure stringent quality control (QC).

While quality assurance (QA) and quality control (QC) processes are interrelated, the legacy technology supporting them is often not. To effectively address this challenge, teams must collaborate and access data from a unified platform. A modern, integrated laboratory information management system (LIMS) can enhance digital collaboration, minimize the risk of errors, and aid the organization in transitioning away from paper-based processes.

Explore common misconceptions that obstruct progress and why overcoming these barriers early provides a competitive edge when preparing for commercialization. With all quality and manufacturing data centralized, companies can shorten lead times and testing duration, as well as improve their audit and inspection readiness.